Qlife Holding AB (publ) (QLIFE.ST)
SEK 1.9
(-1.81%)
SEK 1.9
(-1.81%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 62.16 Million SEK | -38.75% |
| 2022 | 101.5 Million SEK | 235.47% |
| 2021 | 30.25 Million SEK | -19.62% |
| 2020 | 37.64 Million SEK | 166.61% |
| 2019 | 14.11 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 56.78 Million SEK | -8.66% |
| 2024 Q2 | 63.5 Million SEK | 11.84% |
| 2023 Q4 | 62.16 Million SEK | 6.26% |
| 2023 Q2 | 56.41 Million SEK | -51.19% |
| 2023 FY | 62.16 Million SEK | -38.75% |
| 2023 Q1 | 115.57 Million SEK | 13.87% |
| 2023 Q3 | 58.5 Million SEK | 3.71% |
| 2022 Q1 | 29.7 Million SEK | -1.82% |
| 2022 FY | 101.5 Million SEK | 235.47% |
| 2022 Q2 | 106.51 Million SEK | 258.57% |
| 2022 Q3 | 122.22 Million SEK | 14.75% |
| 2022 Q4 | 101.5 Million SEK | -16.96% |
| 2021 FY | 30.25 Million SEK | -19.62% |
| 2021 Q1 | 37.47 Million SEK | -0.45% |
| 2021 Q3 | 19.62 Million SEK | -21.46% |
| 2021 Q4 | 30.25 Million SEK | 54.19% |
| 2021 Q2 | 24.98 Million SEK | -33.32% |
| 2020 Q1 | 8.87 Million SEK | -37.12% |
| 2020 Q2 | 10.7 Million SEK | 20.53% |
| 2020 FY | 37.64 Million SEK | 166.61% |
| 2020 Q4 | 37.64 Million SEK | 220.64% |
| 2020 Q3 | 11.73 Million SEK | 9.7% |
| 2019 FY | 14.11 Million SEK | 0.0% |
| 2019 Q4 | 14.11 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -465.276% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 97.675% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 97.675% |
| Arcoma AB | 33.3 Million SEK | -86.666% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 81.144% |
| BICO Group AB (publ) | 3.26 Billion SEK | 98.096% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 77.789% |
| CellaVision AB (publ) | 212.32 Million SEK | 70.72% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -337.902% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -805.074% |
| C-Rad AB (publ) | 122.4 Million SEK | 49.208% |
| Duearity AB (publ) | 17.53 Million SEK | -254.643% |
| Dignitana AB (publ) | 37.56 Million SEK | -65.488% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -213.985% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.748% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -201.787% |
| Iconovo AB (publ) | 14.55 Million SEK | -327.164% |
| Integrum AB (publ) | 22.07 Million SEK | -181.654% |
| Luxbright AB (publ) | 7 Million SEK | -788.113% |
| Mentice AB (publ) | 163.55 Million SEK | 61.989% |
| OssDsign AB (publ) | 105.25 Million SEK | 40.936% |
| Paxman AB (publ) | 44.5 Million SEK | -39.677% |
| Promimic AB (publ) | 16.15 Million SEK | -284.804% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -192.175% |
| ScandiDos AB (publ) | 37.18 Million SEK | -67.184% |
| Sectra AB (publ) | 1.64 Billion SEK | 96.212% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -41.094% |
| Senzime AB (publ) | 58.06 Million SEK | -7.068% |
| SpectraCure AB (publ) | 14.97 Million SEK | -315.152% |
| Stille AB | 172.64 Million SEK | 63.989% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 98.305% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 75.189% |